Mometasone furoate: A review of its intranasal use in allergic rhinitis

Drugs

Volumn 56, Issue 4, 1998, Pages 725-745

  Onrust, S V ^a   Lamb, H M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; MOMETASONE FUROATE;

ALLERGIC RHINITIS; AQUEOUS SOLUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EPISTAXIS; HEADACHE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRANASAL DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; PHARYNGITIS; POLLEN ALLERGY;

EID: 0031736127     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856040-00018     Document Type: Article

References (71)

1. 1. A Prakash P Benfield 1998 Topical mometasone: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders Drugs 55 145 63 9463794 10.2165/00003495-199855010-00009 1:CAS:528:DyaK1cXntVCmtQ%3D%3D Prakash A, Benfield P. Topical mometasone: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998 Jan; 55: 145–63
2. 2. A Parikh GK Scadding 1997 Seasonal allergic rhinitis BMJ 314 1392 5 9161315 10.1136/bmj.314.7091.1392 1:STN:280:DyaK2szgsFSnsg%3D%3D Parikh A, Scadding GK. Seasonal allergic rhinitis. BMJ 1997 May 10; 314: 1392–5
3. 3. T Levenson PA Greenberger 1997 Pathophysiology and therapy for allergic and nonallergic rhinitis: an updated review Allergy Asthma Proc 18 213 20 9270882 10.2500/108854197778594016 1:STN:280:DyaK2svhs12gsQ%3D%3D Levenson T, Greenberger PA. Pathophysiology and therapy for allergic and nonallergic rhinitis: an updated review. Allergy Asthma Proc 1997 Jul–Aug; 18: 213–20
4. 4. CAJ Janeway P Travers 1994 Immunobiology: the immune system in health and disease Current Biology Ltd./Garland Publishing, Inc. London Janeway CAJ, Travers P. Immunobiology: the immune system in health and disease. London: Current Biology Ltd./Garland Publishing, Inc., 1994
5. 5. CJ Trigg RJ Davies 1996 Local antihistamines Clin Exp Allergy 26 1108 11 8911694 10.1111/j.1365-2222.1996.tb00495.x 1:CAS:528:DyaK2sXitlOksA%3D%3D Trigg CJ, Davies RJ. Local antihistamines. Clin Exp Allergy 1996 Oct; 26: 1108–11
6. 6. WJ Fokkens T Godthelp AF Holm 1997 Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy Allergy 52 36 29 32 9212860 10.1111/j.1398-9995.1997.tb04819.x 1:STN:280:DyaK2szls1Chtg%3D%3D Fokkens WJ, Godthelp T, Holm AF, et al. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy 1997; 52 Suppl. 36: 29–32
7. 7. N Mygind R Dahl 1996 The rationale for use of topical corticosteroids in allergic rhinitis Clin Exp Allergy 26 3 2 10 8735852 10.1111/j.1365-2222.1996.tb00652.x 1:CAS:528:DyaK2sXitlOhtw%3D%3D Mygind N, Dahl R. The rationale for use of topical corticosteroids in allergic rhinitis. Clin Exp Allergy 1996 May; 26 Suppl. 3: 2–10
8. 8. BE Barton JP Jakway SR Smith 1991 Cytokine inhibition by a novel steroid, mometasone furoate Immunopharmacol Immunotoxicol 13 3 251 61 1940049 10.3109/08923979109019704 1:CAS:528:DyaK3MXmsVyhu7o%3D Barton BE, Jakway JP, Smith SR, et al. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol 1991; 13(3): 251–61
9. 9. Therattil J, Chavarria V, Cosachov J, et al. The effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis (SAR) [abstract]. Annual Meeting of the American College of Allergy, Asthma & Immunology 1996: 51
10. 10. SP Umland DK Nahrebne S Razac 1997 The inhibitory effects of topically active glucocorticooids on IL-4, IL-5 and interferon-γ production by cultured primary CD4 + T cells J Allergy Clin Immunol 100 511 9 9338546 10.1016/S0091-6749(97)70144-1 1:CAS:528:DyaK2sXntFCiurw%3D Umland SP, Nahrebne DK, Razac S, et al. The inhibitory effects of topically active glucocorticooids on IL-4, IL-5 and interferon-γ production by cultured primary CD4 + T cells. J Allergy Clin Immunol 1997 Oct; 100: 511–9
11. 11. RW Chapman SJ Sehring CG Garlisi 1998 Anti-inflammatory activity of inhaled mometasone furoate in allergic mice Arzneimittel Forschung 48I 4 384 91 Chapman RW, Sehring SJ, Garlisi CG, et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittel Forschung 1998; 48 (I)(4): 384–91
12. 12. IC Crocker CY Zhou AK Bewtra 1997 Glucocorticosteroids inhibit leukotriene production Ann Allergy Asthma Immunol 78 497 505 9164364 10.1016/S1081-1206(10)63238-3 1:CAS:528:DyaK2sXjs1Cit7s%3D Crocker IC, Zhou CY, Bewtra AK, et al. Glucocorticosteroids inhibit leukotriene production. Ann Allergy Asthma Immunol 1997 May; 78: 497–505
13. 13. EO Meltzer AA Jalowayski HA Orgel 1998 Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray J Allergy Clin Immunol 102 39 49 9679846 10.1016/S0091-6749(98)70053-3 1:CAS:528:DyaK1cXlt1els7k%3D Meltzer EO, Jalowayski AA, Orgel HA, et al. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol 1998; 102: 39–49
14. 14. Schering-Plough Research Institute. The effect of mometasone furoate nasal spray on early and late phase inflammation during in vivo ragweed nasal provocation in patients with seasonal allergic rhinitis. Study no. C93-193 (Data on file)
15. 15. IC Crocker MK Church S Newton 1998 Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines Ann Allergy Asthma Immunol 80 509 16 9647275 10.1016/S1081-1206(10)63075-X 1:CAS:528:DyaK1cXksVSltro%3D Crocker IC, Church MK, Newton S, et al. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines. Ann Allergy Asthma Immunol 1998; 80: 509–16
16. 16. S Chyrek-Borowska AM Rogalewska D Lenczewska 1998 Open study of the efficacy and safety of Nasonex (mometasone furoate) a new intranasal glucocorticosteroid in seasonal allergic rhinitis (SAR) Allergy 53 43 158 Chyrek-Borowska S, Rogalewska AM, Lenczewska D. Open study of the efficacy and safety of Nasonex (mometasone furoate) a new intranasal glucocorticosteroid in seasonal allergic rhinitis (SAR). Allergy 1998 Jun 24; 53 Suppl. 43: 158
17. 17. E Minshall O Ghaffar L Cameron 1998 Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis Otolaryngol Head Neck Surg 118 648 54 9591864 1:STN:280:DyaK1c3lt1Glsw%3D%3D Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998; 118: 648–54
18. 18. U Knutsson P Stierna C Marcus 1995 Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function J Endocrinol 144 301 10 7706983 10.1677/joe.0.1440301 1:CAS:528:DyaK2MXktVGks7s%3D Knutsson U, Stierna P, Marcus C, et al. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol 1995; 144: 301–10
19. 19. GH Williams RG Dluhy 1991 Diseases of the adrenal cortex JD Wilson E Braunwald KJ Isselbacher Principles of internal medicine 12th McGraw-Hill Inc. New York 1713 35 Williams GH, Dluhy RG. Diseases of the adrenal cortex. In: Wilson JD, Braunwald E, Isselbacher KJ, editors. Principles of internal medicine. 12th ed. v. 2. New York: McGraw-Hill Inc., 1991: 1713–35
20. 20. E Meltzer K Nolop B Mesarina-Wicki 1997 A dose-ranging study of mometasone furoate nasal spray in children with seasonal allergic rhinitis [abstract] Allergy 52 37 136 Meltzer E, Nolop K, Mesarina-Wicki B, et al. A dose-ranging study of mometasone furoate nasal spray in children with seasonal allergic rhinitis [abstract]. Allergy 1997; 52 Suppl. 37: 136
21. 21. MD Brannan JM Herron MB Affrime 1997 Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children Clin Ther 19 6 1330 9 9444443 10.1016/S0149-2918(97)80008-2 1:CAS:528:DyaK1cXjslGgsQ%3D%3D Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19(6): 1330–9
22. 22. Schering-Plough Research Institute. SCH 32088: One-year, double-blind study of the effects of mometasone furoate aqueous nasal spray (MFNS) vs. placebo, on growth in children with perennial rhinitis (PR). Study no. C96-094 (Data on file)
23. 23. Brannan MD, Herron JM, Reidenberg P, et al. Lack of HPA axis suppression following 36 days of intranasal mometasone furoate [abstract]. Annual Meeting of the American College of Allergy, Asthma & Immunology 1996: 76
24. 24. MD Brannan M Seiberling DL Cutler 1996 Lack of systemic activity with intranasal mometasone furoate [abstract] J Allergy Clin Immunol 97 198 10.1016/S0091-6749(96)80280-6 Brannan MD, Seiberling M, Cutler DL, et al. Lack of systemic activity with intranasal mometasone furoate [abstract]. J Allergy Clin Immunol 1996 Jan; 97 (Pt 3): 198
25. 25. Meltzer EO, Berger WE, Berkowitz RB, et al. Dose-ranging study of mometasone furoate aqueous nasal spray (Nasonex) in children with seasonal allergic rhinitis. Schering-Plough Research Institute (Data on file)
26. 26. Brannan MD, Herron JM, Reidenberg P. SCH 32088: Multiple-dose comparative systemic bioactivity study of mometasone nasal spray in volunteers with evidence of allergic rhinitis. Schering-Plough Research Institute, 1998, Study no. C93-196 (Data on file)
27. 27. Brannan MD, Seiberling M, Cutler DL. Single-dose comparative systemic bioactivity study of nasally administered mometasone. Schering-Plough Research Institute, Study no. 190-664 (Data on file)
28. 28. Schering-Plough Research Institute. A long-term safety study of SCH 32088 vs Nasacort in perennial rhinitis. Study no. C94-052 (Data on file)
29. 29. Schering-Plough Research Institute. SCH 32088: Single-dose absolute bioavailability study of mometasone furoate administered as an intravenous solution, oral solution, oral suspension and nasal spray — a four-way crossover design. Study no. C95-050-01 (Data on file)
30. 30. BJ Lipworth JR Seckl 1997 Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids Thorax 52 476 82 9176542 10.1136/thx.52.5.476 1:STN:280:DyaK2szhvFKguw%3D%3D Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476–82
31. 31. Schering Corporation. Mometasone furoate monohydrate nasal spray prescribing information. Kenilworth, New Jersey U.S.A., 1997
32. 32. Zbaida S, Shannon D, Du Y, et al. In vitro metabolism of mometasone furoate [abstract no. P339]. 17th International Congress of Biochemistry and Molecular Biology, in conjunction with 1997 Annual Meeting of the American Society for Biochemistry and Molecular Biology 1997 August (special issue): A829
33. 33. Schering-Plough Research Institute. Study no. C97-047-01. (Data on file)
34. 34. EA Bronsky DW Aaronson RB Berkowitz 1997 Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis Ann Allergy Asthma Immunol 79 51 6 9236500 10.1016/S1081-1206(10)63084-0 1:CAS:528:DyaK2sXltlyltbc%3D Bronsky EA, Aaronson DW, Berkowitz RB, et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997 Jul; 79: 51–6
35. 35. JR Hebert K Nolop BN Lutsky 1996 Once-daily mometasone furoate aqueous nasal spray (Nasonex™) in seasonal allergic rhinitis: an active-and placebo-controlled study Allergy 51 569 76 8874661 1:CAS:528:DyaK28XlvVOns7o%3D Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex™) in seasonal allergic rhinitis: an active-and placebo-controlled study. Allergy 1996 Aug; 51: 569–76
36. 36. Bernstein DI, Nolop K, Mesarina-Wicki B, et al. Evaluation of mometasone furoate (Nasonex™) nasal spray in perennial rhinitis [abstract]. Annual Meeting of the American College of Allergy, Asthma & Immunology 1996: 76
37. 37. M Drouin WH Yang B Bertrand 1996 Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients Ann Allergy Asthma Immunol 77 153 60 8760782 10.1016/S1081-1206(10)63502-8 1:CAS:528:DyaK28Xltl2mu7k%3D Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996 Aug; 77: 153–60
38. 38. M Mandl K Nolop BN Lutsky 1997 Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis Ann Allergy Asthma Immunol 79 370 8 9357385 10.1016/S1081-1206(10)63030-X 1:CAS:528:DyaK2sXntlyitbw%3D Mandl M, Nolop K, Lutsky BN, et al. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol 1997 Oct; 79: 370–8
39. 39. Schenkel EJ, Nolop K, Mesarina-Wicki B. Evaluation of mometasone furoate (Nasonex™) nasal spray with the addition of loratadine vs placebo in the treatment of seasonal allergic rhinitis [abstract]. Annual Meeting of the American College of Allergy, Asthma & Immunology 1996: 48
40. 40. D Graft D Aaronson P Chervinsky 1996 A placebo-and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray J Allergy Clin Immunol 98 724 31 8876546 10.1016/S0091-6749(96)70119-7 1:CAS:528:DyaK28XmslKrs74%3D Graft D, Aaronson D, Chervinsky P, et al. A placebo-and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996 Oct; 98: 724–31
41. 41. P Marazzi K Nolop BN Lutsky 1997 Prophylactic use of once-daily mometasone furoate (Nasonex™) aqueous nasal spray in patients with seasonal allergic rhinitis [abstract] J Allergy Clin Immunol 99 S440 Marazzi P, Nolop K, Lutsky BN, et al. Prophylactic use of once-daily mometasone furoate (Nasonex™) aqueous nasal spray in patients with seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 1997 Jan; 99 (Pt 2): S440
42. 42. RB Berkowitz KB Nolop BE Mesarina-Wicki 1997 Onset of action of mometasone furoate (Nasonex) nasal spray in seasonal allergic rhinitis [abstract] J Allergy Clin Immunol 99 S441 Berkowitz RB, Nolop KB, Mesarina-Wicki BE, et al. Onset of action of mometasone furoate (Nasonex) nasal spray in seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 1997 Jan; 99 (Pt 2): S441
43. 43. RB Berkowitz S Roberson J Zora 1998 Onset of action of mometasone furoate nasal spray (MFNS) in seasonal allergic rhinitis (SAR) [abstract no. 1010] J Allergy Clin Immunol 101 S244 Berkowitz RB, Roberson S, Zora J, et al. Onset of action of mometasone furoate nasal spray (MFNS) in seasonal allergic rhinitis (SAR) [abstract no. 1010]. J Allergy Clin Immunol 1998 Jan; 101 (1 Pt 2): S244
44. 44. N Mygind V Lund 1996 Topical corticosteroid therapy of rhinitis: a review Clin Immunother 5 122 36 10.1007/BF03259319 Mygind N, Lund V. Topical corticosteroid therapy of rhinitis: a review. Clin Immunother 1996 Feb; 5: 122–36
45. 45. A Dooms-Goossen J-P Lepoittevin 1996 Studies on the contact allergenic potential of momethasone furoate: a clinical and molecular study Eur J Dermatol 6 339 40 Dooms-Goossen A, Lepoittevin J-P. Studies on the contact allergenic potential of momethasone furoate: a clinical and molecular study. Eur J Dermatol 1996 Jul–Aug; 6: 339–40
46. 46. J-P Lepoittevin J Drieghe A Dooms-Goosens 1995 Studies in patients with corticosteroid contact allergy: understanding cross-reactivity among different steroids Arch Dermatol 131 31 7 7826093 10.1001/archderm.1995.01690130033006 1:STN:280:DyaK2M7is1Kmsg%3D%3D Lepoittevin J-P, Drieghe J, Dooms-Goosens A. Studies in patients with corticosteroid contact allergy: understanding cross-reactivity among different steroids. Arch Dermatol 1995 Jan; 131: 31–7
47. 47. L Räsänen M-L Tuomi 1992 Cross-sensitization to mometasone furoate in patients with corticosteroid contact allergy Contact Dermatitis 27 323 5 1493689 10.1111/j.1600-0536.1992.tb03290.x Räsänen L, Tuomi M-L. Cross-sensitization to mometasone furoate in patients with corticosteroid contact allergy. Contact Dermatitis 1992 Nov; 27: 323–5
48. 48. B Sibbald E Rink 1991 Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history Thorax 46 895 901 1792637 10.1136/thx.46.12.895 1:STN:280:DyaK387mvFGqsQ%3D%3D Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991; 46: 895–901
49. 49. CM Kozma MK Sadik ML Watrous 1996 Economic outcomes for the treatment of allergic rhinitis PharmacoEconomics 10 4 13 10172730 10.2165/00019053-199610010-00002 1:STN:280:DyaK28zmvVCjug%3D%3D Kozma CM, Sadik MK, Watrous ML. Economic outcomes for the treatment of allergic rhinitis. PharmacoEconomics 1996 Jul; 10: 4–13
50. 50. EF Juniper 1997 Measuring health-related quality of life in rhinitis J Allergy Clin Immunol 99 S742 7 9042066 10.1016/S0091-6749(97)90000-2 1:STN:280:DyaK2s7psVKhug%3D%3D Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997 Feb; 99: S742–7
51. 51. J Bousquet M Bullinger C Fayol 1994 Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire J Allergy Clin Immunol 94 182 8 8064070 10.1053/ai.1994.v94.a54939 1:STN:280:DyaK2czkt1Kmtw%3D%3D Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994 Aug; 94 (Pt 1): 182–8
52. 52. International Rhinitis Management Group. International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy 1994 Suppl. 19: 5–34
53. 53. HF Krause 1995 Pharmacotherapy of perennial and seasonal allergic rhinitis Clin Immunother 3 308 24 10.1007/BF03259282 Krause HF. Pharmacotherapy of perennial and seasonal allergic rhinitis. Clin Immunother 1995 Apr; 3: 308–24
54. 54. EO Meltzer 1995 An overview of current pharmacotherapy in perennial rhinitis J Allergy Clin Immunol 95 1097 110 7538519 10.1016/S0091-6749(95)70213-X 1:STN:280:DyaK2M3ntVymtg%3D%3D Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 1995 May; 95 (Pt 2): 1097–110
55. 55. VJ Lund 1995 Practical application of the International Consensus on the Management of Rhinitis Clin Immunother 4 270 8 10.1007/BF03259292 Lund VJ. Practical application of the International Consensus on the Management of Rhinitis. Clin Immunother 1995 Oct; 4: 270–8
56. 56. N Mygind 1993 Glucocorticosteroids and rhinitis Allergy 48 476 90 8238807 10.1111/j.1398-9995.1993.tb01103.x 1:CAS:528:DyaK2cXhsFersbs%3D Mygind N. Glucocorticosteroids and rhinitis. Allergy 1993; 48: 476–90
57. 57. P Chervinsky 1996 Clinical review of once-daily beclomethasone dipropionate for seasonal allergic rhinitis Clin Ther 18 5 790 6 8930423 10.1016/S0149-2918(96)80039-7 1:STN:280:DyaK2s%2FosVSkuw%3D%3D Chervinsky P. Clinical review of once-daily beclomethasone dipropionate for seasonal allergic rhinitis. Clin Ther 1996; 18(5): 790–6
58. 58. JC Seiner RW Weber GW Richmond 1995 Onset of action of aqueous beclomethasone dipropionate nasal spray in seasonal allergic rhinitis Clin Ther 17 6 1099 109 10.1016/0149-2918(95)80088-3 Seiner JC, Weber RW, Richmond GW, et al. Onset of action of aqueous beclomethasone dipropionate nasal spray in seasonal allergic rhinitis. Clin Ther 1995; 17(6): 1099–109
59. 59. JH Day DL Buckeridge RH Clark 1996 A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis J Allergy Clin Immunol 97 1050 7 8626981 10.1016/S0091-6749(96)70257-9 1:CAS:528:DyaK28XjslCltrc%3D Day JH, Buckeridge DL, Clark RH. A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996; 97: 1050–7
60. 60. RA Nathan ED Bronsky P Fireman 1991 Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis Ann Allergy 67 3 332 8 1897811 1:STN:280:DyaK3MznvVSqtg%3D%3D Nathan RA, Bronsky ED, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991 Sep; 67(3): 332–8
61. 61. CF LaForce RJ Dockhorn SR Findlay 1994 Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents Fam Pract 38 145 52 1:STN:280:DyaK2c7ktFCmtg%3D%3D LaForce CF, Dockhorn RJ, Findlay SR, et al. Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. Fam Pract 1994; 38: 145–52
62. 62. W Jeal D Faulds 1997 Triamcinolone acetonide: a review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis Drugs 53 257 80 9028745 10.2165/00003495-199753020-00006 1:CAS:528:DyaK2sXht1akt74%3D Jeal W, Faulds D. Triamcinolone acetonide: a review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 1997 Feb; 53: 257–80
63. 63. MD Brannan JM Herron P MB Reidenberg 1995 Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis Clin Ther 17 637 47 8565027 10.1016/0149-2918(95)80040-9 1:STN:280:DyaK28%2FpvVegsg%3D%3D Brannan MD, Herron JM, Reidenberg PA MB. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther 1995; 17: 637–47
64. 64. Dura Pharmaceuticals Inc. 1998 Beclomethasone dipropionate product information R Arky Physicians’ desk reference 52nd Medical Economics, Inc. Montvale (NJ). 1006 8 Dura Pharmaceuticals Inc. Beclomethasone dipropionate product information. In: Arky R, editor. Physicians’ desk reference. 52nd ed. Montvale (NJ). Medical Economics, Inc., 1998: 1006–8
65. 65. Rhone-Poulenc Rorer Pharmaceuticals Inc. 1998 Triamcinolone acetonide aerosol prescribing information R Arky Physicians’ desk reference 52nd Medical Economics Company, Inc. Montvale (NJ). 2371 3 Rhone-Poulenc Rorer Pharmaceuticals Inc. Triamcinolone acetonide aerosol prescribing information. In: Arky R, editor. Physicians’ desk reference. 52nd ed. Montvale (NJ). Medical Economics Company, Inc., 1998: 2371–3
66. 66. Rhone-Poulenc Rorer Pharmaceuticals Inc. 1998 Triamcinolone acetonide aqueous spray prescribing information R Arky Physicians’ desk reference 52nd Medical Economics Company, Inc. Montvale, (NJ). 2373 4 Rhone-Poulenc Rorer Pharmaceuticals Inc. Triamcinolone acetonide aqueous spray prescribing information. In: Arky R, editor. Physicians’ desk reference. 52nd ed. Montvale, (NJ). Medical Economics Company, Inc., 1998: 2373–4
67. 67. Glaxo Wellcome Inc. 1998 Fluticasone propionate product information R Arky Reviews Physicians’ desk reference 52nd Medical Economics Company, Inc. Montvale (NJ) 1025 7 Glaxo Wellcome Inc. Fluticasone propionate product information. In: Arky R, editor. ReviewsPhysicians’ desk reference. 52nd ed. Montvale (NJ): Medical Economics Company, Inc., 1998: 1025–7
68. 68. Astra USA Inc. 1998 Budesonide product information R Arky Reviews Physicians’ desk reference 52nd Medical Economics Company Montvale (NJ). 572 4 Astra USA Inc. Budesonide product information. In: Arky R, editor. ReviewsPhysicians’ desk reference. 52nd ed. Montvale (NJ). Medical Economics Company, 1998: 572–4
69. 69. LR Wiseman P Benfield 1997 Intranasal fluticasone propionate: a reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis Drugs 53 885 907 9129872 10.2165/00003495-199753050-00014 1:CAS:528:DyaK2sXjtFOjsLg%3D Wiseman LR, Benfield P. Intranasal fluticasone propionate: a reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997 May; 53: 885–907
70. 70. RN Brogden D McTavish 1992 Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis Drugs 44 3 375 407 1382936 10.2165/00003495-199244030-00007 1:STN:280:DyaK3s%2FhtVCmsw%3D%3D Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44(3): 375–407
71. 71. DV Belsito 1993 Allergic contact dermatitis to topical glucocortico-steroids Cutis 52 291 4 8299391 1:STN:280:DyaK2c7jtVGktg%3D%3D Belsito DV. Allergic contact dermatitis to topical glucocortico-steroids. Cutis 1993 Nov; 52: 291–4